• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Hawkins departure indicates shift in strategy

Hawkins departure indicates shift in strategy

December 21, 2010 By MedCity News

MDT logo

When Medtronic Inc. (NYSE:MDT) CEO Art Collins retired in 2007, there were at least two candidates vying to replace him.

One was Michael DeMane, the brash president of Fridley, Minn.-based medical device giant’s spine business whose aggressive pursuit of growth invited legal and regulatory scrutiny. The other was chief operating officer Bill Hawkins, a steady, stabilizing presence within Medtronic’s senior leadership team.

The COO ultimately prevailed. Yet Medtronic said Monday that Hawkins will retire in April 2011, less than five years after assuming the top job. Given Hawkins’ relatively short tenure as CEO — Collins served six years, William George ten years — the announcement surprised analysts though some believed the move was necessary.

MedCity News logo

“Today’s news from Medtronic is surprising … in terms of timing, but thematically in line with our expectations and an encouraging signal of the Board’s desire for accelerated value generation,” Morgan Stanley analyst David Lewis wrote in a research note.

“We expect investors to view this announcement as indicative that a focus on cash flow is likely to become more acute, and this should support positive price movements as a signal of focus on shareholder returns and operational adaptation to the new operating environment,” Lewis wrote.

Hawkins was regarded by most as a smart and capable leader. Under his leadership, Medtronic reorganized its businesses under his “One Medtronic” initiative, expanded overseas and made several “tuck-in” acquisitions. But Hawkins’ efforts went largely unrewarded on Wall Street.

Since August 2007, the month Hawkins became CEO, Medtronic shares have fallen 30 percent to $37 from $53, though that period also includes the worst economic recession in American history since the Great Depression.

But Medtronic also was hampered by operational missteps, including the Sprint Fidelis debacle and continued problems in its spine business. Medtronic has downgraded its 2011 profit forecast twice this year.

But Medtronic also faces a vastly different industry than in the days of Collins and George. Its core pacemaker and implantable cardioverter defibrillator businesses no longer are growth drivers. Healthcare reform — financed in part by a $20 billion tax on medical device makers — has made Medtronic’s long-term business prospects less certain.

“Hawkins became CEO at a very difficult time for Medtronic, and he will be leaving at a very difficult time for Medtronic,” said Joseph Galatowitsch, president and managing partner for Dymedex Consulting in Woodbury, Minn.

Medtronic is transitioning from a high-growth, double-digit growth engine to a more mature business where mid-to-high single digits are the norm, Galatowitsch said.

In response, Medtronic under Hawkins made several small to mid-sized acquisitions. Over the past two years, the company has purchased nine companies: $700 million for CoreValve Inc.; $370 million for ATS Medical Inc.; $123 million for Osteotech Inc., to name a few.

But Hawkins’ “tuck-in” acquisitions never caught fire with Wall Street. In the end, one has to wonder if Hawkins’ inherent caution contributed to his departure. In an industry ripe for consolidation, Medtronic had the cash but not the nerve to pursue big deals.

Who will replace Hawkins and what will their acquisition strategy be? Medtronic said it would pursue a candidate outside of the company — a strong indication it wants new blood to recharge its businesses. George, Collins and Hawkins all were Medtronic executives before the company tapped them for CEO.

In short, Medtronic wants bold leadership. And perhaps nothing says bold more than an industry-changing acquisition or two.

“We are very encouraged the company is so focused on looking externally as we believe external expertise could be helpful given the challenges Medtronic is facing,” Lewis wrote. “We would not be surprised to see additional changes and strategic disruption over the next 12 months given the likely transition to an external candidate could carry an expectation for meaningful changes to strategy and opens the door to additional management changes, acquisitions and divestitures.”

Hawkins might have been the right CEO in 2007, but pressures from both inside and outside the company may have necessitated new leadership for the company for the future.

On the same day of the announcement of Hawkins’ forthcoming exit, Medtronic announced that one of its former CEOs had died.

Winston Wallin, who lead Medtronic from 1985 to 1991, died Monday at age 84. A former president and chief operating officer at Pillsbury Co., Wallin joined Medtronic as a board member in 1978 and was named CEO seven years later.

“We are saddened to learn of Win’s passing, and our thoughts and prayers are with the Wallin family as they grieve the loss and celebrate the life of a dedicated family man and community leader,” Hawkins said in a statement.

“Win’s legacy is part of the very heart of Medtronic,” he said. “Without his contributions, Medtronic would not be what it is today. We are grateful for the opportunity to remember his leadership at Medtronic with pride, and we are inspired to carry out our Mission with the same devotion and passion that he did.”

In retirement, Wallin was an active philanthropist. He founded Wallin Education Partners, an integral partner to the Medtronic Foundation’s Scholars program. Since 1991, the program has awarded more than 3,000 scholarships and more than $25 million to support high-potential students with financial need from Minneapolis, Anoka-Hennepin, St. Paul and North Metro district high schools.

Earlier this year, the University of Minnesota named its new medical biosciences building, a key facility in the school’s $292 million Biomedical Discovery District, after Wallin and his wife Maxine.

“We fondly remember Win for much more than his business record,” Hawkins said. “He was extraordinarily generous and kind, and had a sincerity and dedication to fairness and ethical business practices which we strive to uphold every day at Medtronic.”

To listen to a November podcast with Medtronic CEO Bill Hawkins, click here.

Filed Under: Business/Financial News, News Well Tagged With: Personnel Moves

In case you missed it

  • Texas power grid struggles a year after cold stopped semiconductor plants
  • The road to a robot: Medtronic’s development process for Hugo RAS system
  • How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
  • Zimmer Biomet appoints new chief accounting officer
  • Cook Medical makes next-gen in vitro fertilization incubator available in U.S., Canada
  • Boston Scientific co-founder Peter Nicholas is dead at 80
  • How Boston Scientific uses clinical feedback to advance innovation
  • How Stryker includes users for product design in the digital age
  • DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
  • FDA approves Medtronic’s Onyx Frontier drug-eluting coronary stent
  • Medtronic completes Intersect ENT acquisition
  • Steris rises on Street-beating Q4, sets fiscal 2023 guidance
  • Medtronic must sell Intersect ENT subsidiary to satisfy FTC concerns
  • Abbott partners with Women as One to help more underrepresented clinicians lead trials
  • Lucira Health asks FDA for EUA on molecular at-home COVID/flu test
  • Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring
  • Abbott announces availability of Xience Skypoint drug-eluting stent in extended sizes

RSS From Medical Design & Outsourcing

  • Texas power grid struggles in heat one year after record cold stopped semiconductor plants
    A heat wave in Texas took at least six power plants offline Friday with high temperatures forecasted to blaze throughout this week. A record cold snap in February 2021 took NXP Semiconductors and Samsung chip fabrication facilities offline for weeks, contributing to a global semicondcutor shortage that is still throttling medical device production. There’s no… […]
  • How Stryker includes users for product design in the digital age
    Medical device developers and manufacturers like Stryker (NYSE:SYK) are changing how they approach design as digital technology becomes more crucial. Four Stryker executives shared how the Kalamazoo, Michigan–based orthopedic device giant is thinking differently about medical product development and how health care providers and patients will ultimately use them. The DeviceTalks Boston panel of Stryker… […]
  • DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
    DermaSensor Inc. — the creator of a handheld, point-and-click device to quickly assess skin lesions for cancer risk — is the winner of the MedTech Innovator Mid-Stage Companies Pitch Event.  The Miami-based mid-stage company beat out 1,000 applicants, more than 20 of which competed on-site May 10–11, 2022 at DeviceTalks Boston. DermaSensor walked away with… […]
  • Steris rises on Street-beating Q4, sets fiscal 2023 guidance
    Steris (NYSE:STE) shares ticked up today on fourth-quarter financial results that came in just ahead of the consensus forecast. The infection prevention technology company — headquartered in Dublin, Ireland, and run operationally out of Mentor, Ohio — posted profits of $52.3 million, or 52¢ per share, on sales of $1.2 billion for the three months… […]
  • Lucira Health asks FDA for EUA on molecular at-home COVID/flu test
    Lucira Health (Nasdaq: LHDX) today said it has asked the FDA for an emergency use authorization (EUA) for its combination COVID-19 and flu test. Emeryville, California–based Lucira said the at-home test would be available with a prescription to test for SARS-CoV-2, Influenza A and Influenza B. The Nucleic Acid Amplification Test (NAAT) platform has a… […]
  • Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring
    AcuityMD said today it has raised $31 million in Series A funding for its medical device commercialization platform. “With our new funding, we plan to double down on R&D by growing our engineering team from 15 to over 40 over the next year,” AcuityMD co-founder and CEO Michael Monovoukas said in a blog post. “We’ll… […]
  • Rockley Photonics announces $81.5M private placement
    Rockley Photonics (NYSE:RKLY) announced today that it entered into agreements for an $81.5 million private placement. Participating investors agreed to purchase $81.5 million in convertible senior secured notes (due 2026) and warrants to purchase 26.5 million Rockley ordinary shares at an exercise price of $5 per share, subject to certain anti-dilution adjustments. Warrants purchased in… […]
  • Stryker leaders talk medtech trends at DeviceTalks Boston: ‘If you’re slow, you’re going to lose’
    The first day of DeviceTalks Boston closed with a panel of Stryker (NYSE:SYK) executives discussing new tools, technologies and strategies in medtech. Digital VP Tracy Robertson, Digital, Robotics, and Enabling Technologies President Robert Cohen and Surgical Technologies VP of Digital Innovation Siddarth Satish offered their thoughts on industry trends in healthcare and at the Kalamazoo,… […]
  • Medtronic’s VC leader discusses risk, returns, strategy and an ‘ugly truth’
    A panel of medtech investors convened today for DeviceTalks Boston included David Neustaedter, VP of venture capital at Medtronic (NYSE: MDT). He’s spent 14 years in the role, including as director of venture capital at Covidien before Medtronic acquired the company. (Read more in his DeviceTalks speaker bio.) Medtronic has more than $500 million in… […]
  • Here’s where Harvard’s engineering dean sees medtech research going
    Surgical robotics, artificial intelligence, and combatting climate change are but some of the priorities that have Harvard’s engineering school dean excited. Speaking today at DeviceTalks Boston, Frank J. Doyle III described the Harvard John A. Paulson School of Engineering and Applied Sciences as a “well-kept secret” historically. But Harvard engineering is staking out a strong position when it… […]
  • gBETA Medtech accelerator picks its next startups
    The gBETA Medtech virtual accelerator today named the five startups that will participate in the spring program leading up to the June 21 showcase day. The five startups for the spring 2022 cohort are: Mother of Fact: This mobile app for moms with babies offers nutrition tracking, preventative monitoring and daily coaching from licensed dietitians… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS